NOVAVAX INC
NVAXNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $6.20 β $13.39
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 164.9M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $1.12B
- Last Q Revenue
- $68M
- P/E Ratio
- β
- P/S Ratio
- 3.2x
- EPS (TTM)
- $-1.54
- Dividend Yield
- β
- Dilution (1yr)
- +8.0%
NOVAVAX INC
NVAXAbout NOVAVAX INC
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.